AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 302
- Registration Number
- NCT01395524
- Locations
- 🇺🇸
Reserach Site, Indianapolis, Indiana, United States
🇸🇰Research Site, Presov, Slovakia
Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Completed
- Conditions
- Cardiovascular Events
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT01395550
A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT01394601
- Locations
- 🇷🇺
Research Site, Samara, Russian Federation
🇷🇺Clinical Site, S-Petersburg, Russian Federation
A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2011-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01392820
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01392807
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusHigh HbA1c LevelInadequate Glycaemic Control
- Interventions
- Drug: placebo
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 311
- Registration Number
- NCT01392677
- Locations
- 🇪🇸
Research Site, Sta Coloma de Gramenet (BCN), Spain
IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder
Completed
- Conditions
- SchizophreniaBipolar Disorder
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 751725
- Registration Number
- NCT01392482
- Locations
- 🇮🇹
Research Site, Rome, Italy
Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2011-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01387308
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT01384292
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 113505
- Registration Number
- NCT01377935